RVXCF - Resverlogix To Release Phase 3 Clinical Trial Data On A First-In-Class BET Bromodomain Inhibitor
Resverlogix is a few days away from releasing topline results from their phase 3 clinical trial, BETonMACE, a trial that aims at showing that Apabetalone (RVX208), a BET bromodomain inhibitor, reduces the risk of heart attacks, stroke and cardiac death in a high-risk population of diabetes patients with low HDL and established cardiovascular disease. The last patient has received the last dose of Apabetalone (or placebo), the last patient has had the last follow-up and the database lock took place on September 19. Management has put out “on or about September 30” as the date